Event Information

Time：April 24, 2015 (Friday)
Place：TRPMA Conference Room

TRPMA invited Dr. Raoh-Fang Pwu of the CDE to talk about the role and importance of HTA in NHI new drug pricing. The information is valuable to new drug manufacturers for the preparation of Health Technology Assessment (HTA) dossiers and the applications of NHI prices.

HTA is an important scientific tool to support health authorities’ decision-making process. In Taiwan, after receiving a new drug listing application, the NHIA will commission the CDE’s HTA Committee to produce an HTA report for reference. The contents of an HTA report include: target patients, reference products for pricing, comparative efficacy, cost effectiveness, budget impact, committee’s recommendation, etc. The Joint Meeting for PBRS and the MOHW will refer to the report and make the final decision.

Dr. Pwu explained to the audience about the recent development and international trend of HTA. The WHA passed the “Health intervention and technology assessment in support of universal health coverage” last year. This decision will affect all health authorities in formulating their HTA systems. Drug manufacturers should watch the movement closely and prepare to adapt to the changes.